Global Corifollitropin Alfa Market Size By Type (Industrial Grade, Pharmaceutical Grade), By Application (Hospitals, Laboratories), By Region, And Segment Forecasts, 2023 to 2032

The Global Corifollitropin Alfa Market was valued at USD 412.6 million in 2023 and is expected to surpass USD 732.4 million by 2031, expanding at a CAGR of 7.3% during the forecast period from 2023 to 2031. Corifollitropin alfa, a recombinant hormone used in controlled ovarian stimulation (COS), is gaining prominence due to its effectiveness in assisted reproductive technologies (ART) such as in-vitro fertilization (IVF). Its ability to reduce the number of injections required during treatment offers greater convenience and compliance for patients, contributing to its rising adoption worldwide.

Drivers:

1. Rising Incidence of Infertility:

Increasing infertility rates due to lifestyle changes, delayed childbearing, and health disorders such as polycystic ovary syndrome (PCOS) and endometriosis are major growth drivers. The global demand for ART procedures is growing steadily, fueling the market for corifollitropin alfa.

2. Advancements in Reproductive Technologies:

Technological progress in ART and hormone therapies has led to the development of safer and more effective fertility drugs. Corifollitropin alfa stands out due to its long-acting nature and reduced need for daily injections, improving patient adherence.

3. Growing Awareness and Access to Fertility Treatments:

Public awareness regarding infertility treatments is increasing globally, supported by healthcare campaigns and social acceptance. Additionally, improved healthcare access and insurance coverage for fertility treatments in several countries are boosting market growth.

Restraints:

1. High Cost of Treatment:

Corifollitropin alfa is more expensive than conventional follicle-stimulating hormone (FSH) treatments, posing a challenge for affordability, especially in low- and middle-income countries.

2. Side Effects and Contraindications:

Potential side effects such as ovarian hyperstimulation syndrome (OHSS) and the drug’s contraindication in certain health conditions can limit its usage and hinder market expansion.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies like India, China, and Brazil are witnessing rising demand for fertility treatments due to growing middle-class populations, urbanization, and increased medical tourism. This presents a significant opportunity for market players to expand their reach.

2. Ongoing Clinical Research and Approvals:

Continuous R&D efforts to improve efficacy and safety, along with regulatory approvals for expanded indications, are expected to open new avenues for corifollitropin alfa.

Market by System Type Insights:

Corifollitropin alfa is primarily available in two formulations based on the required dosing for different body weights: one for women under 60 kg and another for women over 60 kg. In 2023, the higher dosage variant (for women over 60 kg) dominated the market due to increased adoption among broader patient profiles in ART centers, particularly in North America and Europe.

Market by End-use Insights:

By end-use, the Fertility Clinics segment accounted for the largest market share in 2023, driven by the growing number of specialized reproductive health centers and rising ART procedure volumes. The Hospital Pharmacies segment is also projected to grow steadily due to increasing patient admissions and prescriptions by fertility specialists.

Market by Regional Insights:

North America held the largest market share in 2023, owing to the region’s advanced fertility treatment infrastructure, supportive insurance policies, and rising infertility cases. Europe followed closely due to favorable regulatory frameworks and high awareness. The Asia-Pacific region is expected to witness the fastest growth, driven by a burgeoning patient population, improving healthcare infrastructure, and increasing ART demand in countries like China, India, and South Korea.

Competitive Scenario:

Leading companies in the global Corifollitropin Alfa Market include Merck & Co., Inc., Ferring Pharmaceuticals, EMD Serono, and Livzon Pharmaceutical Group. These firms are focusing on R&D, strategic collaborations with fertility clinics, and expanding geographic reach. Notable developments include:

2023: Ferring Pharmaceuticals initiated a post-marketing surveillance program to evaluate long-term safety outcomes of corifollitropin alfa in real-world ART practices.

2024: Merck announced a partnership with a network of IVF centers across Asia to promote access and training on optimal use of corifollitropin alfa.

Scope of Work – Global Corifollitropin Alfa Market

Key Market Developments:

2023: Ferring Pharmaceuticals launched a digital platform to track corifollitropin alfa administration, improving patient compliance and monitoring.

2024: Merck expanded its product availability in Latin America by forming a distribution alliance with regional healthcare providers.

2025: Clinical trial results showed improved success rates of corifollitropin alfa in women undergoing IVF over age 38, driving expanded use.

FAQs:

1. What is the current market size of the Global Corifollitropin Alfa Market?

The market was valued at USD 412.6 million in 2023.

2. What is the major growth driver of the Global Corifollitropin Alfa Market?

The key driver is the rising incidence of infertility coupled with advancements in assisted reproductive technologies.

3. Which is the largest region during the forecast period in the Global Corifollitropin Alfa Market?

North America is the leading region due to its robust healthcare infrastructure and high ART adoption rate.

4. Which segment accounted for the largest market share in the Global Corifollitropin Alfa Market?

The Fertility Clinics segment accounted for the largest share by end-use in 2023.

5. Who are the key market players in the Global Corifollitropin Alfa Market?

Major players include Merck & Co., Inc., Ferring Pharmaceuticals, EMD Serono, and Livzon Pharmaceutical Group.